The natural course of type 2 diabetes involves progressive loss of beta cell function and subsequent loss of glycemic control with oral antidiabetic drugs. Options for initiating insulin include ...

Please provide your email address to receive an email when new articles are posted on . Compared with long-acting insulin analogues and noninsulin anti-diabetic agents, premixed insulin analogues may ...

Sept. 18 -- WEDNESDAY, Sept. 17 (HealthDay News) -- Premixed insulin, which combines short- and long-acting versions of the hormone, results in better blood-sugar control as compared with long-acting ...

Inpatient treatment with premixed human insulin produces glycemic control similar to that of basal-bolus analog regimens in those with type 2 diabetes, but the former led to far higher rates of ...

PARIS, June 28, 2021 /PRNewswire/ -- A new study of Soliqua ® 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL, iGlarLixi, met its two primary endpoints and all key ...

(HealthDay News) — For hospitalized patients with diabetes, treatment with premixed insulin results in similar glycemic control but higher frequency of hypoglycemia compared with a basal-bolus regimen ...

Years ago, Sanofi's Soliqua hit the diabetes market with the promise of combining an insulin and a GLP-1 medicine in a convenient once-daily treatment option for Type 2 diabetes. So far, though, sales ...

NEW YORK A study published in the Sept. 16 issue of the Annals of Internal Medicine has found that premixed insulin provides better blood-sugar control than long-acting insulin or oral medications.

SAN DIEGO — An insulin product made by Eli Lilly appears likely to be more cost-effective than long-acting insulin analog, according to a study presented Friday at the American Diabetes Association’s ...

Study also shows more people on Soliqua had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin ...